Methylenetetrahydrofolate reductase C677T genotype and PD
- PMID: 15929053
- DOI: 10.1002/ana.20509
Methylenetetrahydrofolate reductase C677T genotype and PD
Abstract
In a prospective, population-based cohort study among 5,920 participants aged 55 years or older, we observed that the TT variant of the methylenetetrahydrofolate reductase C677T polymorphism is associated with an increased risk for Parkinson's disease in smokers. Both smoking and the TT genotype are known to induce hyperhomocystinemia, and synergistic effects on homocysteine levels have been reported. Increased plasma levels of homocysteine through direct neurotoxic effects might accelerate the selective dopaminergic cell death underlying Parkinson's disease. Our findings support the hypothesis that homocysteine plays a role in the pathogenesis of Parkinson's disease.
Comment in
-
Methylenetetrahydrofolate reductase in Parkinson's disease.Ann Neurol. 2005 Dec;58(6):972-3. doi: 10.1002/ana.20696. Ann Neurol. 2005. PMID: 16315277 No abstract available.
Similar articles
-
5,10-methylenetetrahydrofolate reductase C677T gene polymorphism can influence age at onset of Parkinson's disease.Acta Neurol Taiwan. 2007 Sep;16(3):150-7. Acta Neurol Taiwan. 2007. PMID: 17966954
-
Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson's disease, with and without levodopa therapy.J Neurol Sci. 2006 Oct 25;248(1-2):56-61. doi: 10.1016/j.jns.2006.05.040. Epub 2006 Jun 13. J Neurol Sci. 2006. PMID: 16774768 Clinical Trial.
-
Hyperhomocysteinemia and methylenetetrahydrofolate reductase polymorphism in patients with Parkinson's disease.Neurosci Lett. 2006 Aug 14;404(1-2):56-60. doi: 10.1016/j.neulet.2006.05.040. Epub 2006 Jun 19. Neurosci Lett. 2006. PMID: 16787708
-
Homocysteine, methylenetetrahydrofolate reductase and risk of schizophrenia: a meta-analysis.Mol Psychiatry. 2006 Feb;11(2):143-9. doi: 10.1038/sj.mp.4001746. Mol Psychiatry. 2006. PMID: 16172608 Review.
-
The role of one-carbon metabolism and homocysteine in Parkinson's disease onset, pathology and mechanisms.Nutr Res Rev. 2019 Dec;32(2):218-230. doi: 10.1017/S0954422419000106. Epub 2019 Jul 15. Nutr Res Rev. 2019. PMID: 31303188 Review.
Cited by
-
Effect of MTHFR polymorphisms on hyperhomocysteinemia in levodopa-treated Parkinsonian patients.Neuromolecular Med. 2007;9(3):249-54. doi: 10.1007/s12017-007-8006-x. Neuromolecular Med. 2007. PMID: 17914182
-
Homocysteine in Neurology: A Possible Contributing Factor to Small Vessel Disease.Int J Mol Sci. 2021 Feb 19;22(4):2051. doi: 10.3390/ijms22042051. Int J Mol Sci. 2021. PMID: 33669577 Free PMC article. Review.
-
Homocysteine, Cognitive Functions, and Degenerative Dementias: State of the Art.Biomedicines. 2022 Oct 28;10(11):2741. doi: 10.3390/biomedicines10112741. Biomedicines. 2022. PMID: 36359260 Free PMC article. Review.
-
Nutritional Risk Factors, Microbiota and Parkinson's Disease: What Is the Current Evidence?Nutrients. 2019 Aug 14;11(8):1896. doi: 10.3390/nu11081896. Nutrients. 2019. PMID: 31416163 Free PMC article. Review.
-
The Controversial Role of Homocysteine in Neurology: From Labs to Clinical Practice.Int J Mol Sci. 2019 Jan 8;20(1):231. doi: 10.3390/ijms20010231. Int J Mol Sci. 2019. PMID: 30626145 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical